Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies

Research output: Contribution to journalReview article

23 Citations (Scopus)

Abstract

Cancer is a major health burden worldwide, and despite continuous advances in medical therapies, resistance to standard drugs and adverse effects still represent an important cause of therapeutic failure. There is a growing evidence that gut bacteria can affect the response to chemo- and immunotherapeutic drugs by modulating either efficacy or toxicity. Moreover, intratumor bacteria have been shown to modulate chemotherapy response. At the same time, anticancer treatments themselves significantly affect the microbiota composition, thus disrupting homeostasis and exacerbating discomfort to the patient. Here, we review the existing knowledge concerning the role of the microbiota in mediating chemo- and immunotherapy efficacy and toxicity and the ability of these therapeutic options to trigger dysbiotic condition contributing to the severity of side effects. In addition, we discuss the use of probiotics, prebiotics, synbiotics, postbiotics, and antibiotics as emerging strategies for manipulating the microbiota in order to improve therapeutic outcome or at least ensure patients a better quality of life all along of anticancer treatments.

Original languageEnglish
Number of pages1
JournalMicrobiome
Volume6
Issue number1
DOIs
Publication statusPublished - May 22 2018

Fingerprint

Microbiota
Drug Interactions
Therapeutics
Synbiotics
Bacteria
Drug Therapy
Prebiotics
Probiotics
Pharmaceutical Preparations
Immunotherapy
Homeostasis
Quality of Life
Anti-Bacterial Agents
Neoplasms

Keywords

  • Cancer
  • Chemotherapy
  • Immunotherapy
  • Metagenomics
  • Microbiota

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Cite this

@article{7a53ac5a9b0c429ca05b95174050d634,
title = "Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies",
abstract = "Cancer is a major health burden worldwide, and despite continuous advances in medical therapies, resistance to standard drugs and adverse effects still represent an important cause of therapeutic failure. There is a growing evidence that gut bacteria can affect the response to chemo- and immunotherapeutic drugs by modulating either efficacy or toxicity. Moreover, intratumor bacteria have been shown to modulate chemotherapy response. At the same time, anticancer treatments themselves significantly affect the microbiota composition, thus disrupting homeostasis and exacerbating discomfort to the patient. Here, we review the existing knowledge concerning the role of the microbiota in mediating chemo- and immunotherapy efficacy and toxicity and the ability of these therapeutic options to trigger dysbiotic condition contributing to the severity of side effects. In addition, we discuss the use of probiotics, prebiotics, synbiotics, postbiotics, and antibiotics as emerging strategies for manipulating the microbiota in order to improve therapeutic outcome or at least ensure patients a better quality of life all along of anticancer treatments.",
keywords = "Cancer, Chemotherapy, Immunotherapy, Metagenomics, Microbiota",
author = "Concetta Panebianco and Angelo Andriulli and Valerio Pazienza",
year = "2018",
month = "5",
day = "22",
doi = "10.1186/s40168-018-0483-7",
language = "English",
volume = "6",
journal = "Microbiome",
issn = "2049-2618",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Pharmacomicrobiomics

T2 - exploiting the drug-microbiota interactions in anticancer therapies

AU - Panebianco, Concetta

AU - Andriulli, Angelo

AU - Pazienza, Valerio

PY - 2018/5/22

Y1 - 2018/5/22

N2 - Cancer is a major health burden worldwide, and despite continuous advances in medical therapies, resistance to standard drugs and adverse effects still represent an important cause of therapeutic failure. There is a growing evidence that gut bacteria can affect the response to chemo- and immunotherapeutic drugs by modulating either efficacy or toxicity. Moreover, intratumor bacteria have been shown to modulate chemotherapy response. At the same time, anticancer treatments themselves significantly affect the microbiota composition, thus disrupting homeostasis and exacerbating discomfort to the patient. Here, we review the existing knowledge concerning the role of the microbiota in mediating chemo- and immunotherapy efficacy and toxicity and the ability of these therapeutic options to trigger dysbiotic condition contributing to the severity of side effects. In addition, we discuss the use of probiotics, prebiotics, synbiotics, postbiotics, and antibiotics as emerging strategies for manipulating the microbiota in order to improve therapeutic outcome or at least ensure patients a better quality of life all along of anticancer treatments.

AB - Cancer is a major health burden worldwide, and despite continuous advances in medical therapies, resistance to standard drugs and adverse effects still represent an important cause of therapeutic failure. There is a growing evidence that gut bacteria can affect the response to chemo- and immunotherapeutic drugs by modulating either efficacy or toxicity. Moreover, intratumor bacteria have been shown to modulate chemotherapy response. At the same time, anticancer treatments themselves significantly affect the microbiota composition, thus disrupting homeostasis and exacerbating discomfort to the patient. Here, we review the existing knowledge concerning the role of the microbiota in mediating chemo- and immunotherapy efficacy and toxicity and the ability of these therapeutic options to trigger dysbiotic condition contributing to the severity of side effects. In addition, we discuss the use of probiotics, prebiotics, synbiotics, postbiotics, and antibiotics as emerging strategies for manipulating the microbiota in order to improve therapeutic outcome or at least ensure patients a better quality of life all along of anticancer treatments.

KW - Cancer

KW - Chemotherapy

KW - Immunotherapy

KW - Metagenomics

KW - Microbiota

UR - http://www.scopus.com/inward/record.url?scp=85053112661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053112661&partnerID=8YFLogxK

U2 - 10.1186/s40168-018-0483-7

DO - 10.1186/s40168-018-0483-7

M3 - Review article

C2 - 29789015

AN - SCOPUS:85053112661

VL - 6

JO - Microbiome

JF - Microbiome

SN - 2049-2618

IS - 1

ER -